Transcription profiling of human tumor cell line TPC-1 treated with siRNAs targetting RET mRNA and the RET/PTC1 junction

ABSTRACT: Genomic rearrangements leading to intragenic gene fusion are mainly found in some types of haematopoietic malignancies and sarcomas. Recently they have been described also in carcinomas such as the papillary thyroid histotype (60%-70%) and the Hürthle thyroid tumours (58%). The presence of junction oncogene constitutes an area of exciting research for emerging therapy as targeting the RET-PTC1 fusion oncogene by using small interfering RNA (siRNA) strategies since it is present only in the tumour cells and not in the surrounding normal cells. Therefore, we developed a siRNA against RET-PTC1 junction and assess its efficiency on the human papillary thyroid carcinoma cell line TPC-1 which spontaneously harbours the RET-PTC1 oncogene. The targeted genes are assessed by microarray analysis by

ORGANISM(S): Homo sapiens

SUBMITTER: Hugues RIPOCHE 

PROVIDER: E-TABM-746 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress